Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Erosive esophagitis associated with GERD
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Maintenance of healing of erosive esophagitis
* Treatment of *Helicobacter pylori* infection (in combination therapy)
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally or intravenously twice daily; titrate as needed. Maximum dose is 120 mg IV daily or 240 mg PO daily divided into two doses.
* ***H. pylori* eradication (triple therapy):** 40 mg orally twice daily for 7-14 days, in combination with specific antibiotics.
* **IV administration:** 40 mg (or 20 mg for less severe GERD) diluted in 100 mL of 0.9% NaCl and infused over 15 minutes. Doses up to 120 mg can be given as a continuous infusion over 24 hours.
## Pediatric Dosing
* **Erosive esophagitis (GERD-associated):**
* 1 to 5 years: 10 mg orally once daily.
* 5 to 12 years: 20 mg orally once daily.
* 12 to 17 years: 40 mg orally once daily.
* Treatment duration typically 4-8 weeks.
* **IV Dosing in Pediatric Patients:** Dosing varies and is often guided by clinical response and weight. Consult specific pediatric guidelines or literature for detailed IV dosing recommendations.
## Dose Adjustments
No dose adjustment is generally needed for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, headache, abdominal pain, nausea, dizziness.
* **Serious/Long-term use:** Bone fractures (hip, wrist, spine), *Clostridium difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency, systemic lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** May decrease absorption of drugs requiring acidic environments (e.g., ketoconazole, itraconazole, iron salts, vitamin B12).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19; monitor for potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, seizures, tetany).
* Monitor for signs of *C. difficile* infection.
* Consider monitoring vitamin B12 levels and bone mineral density with prolonged therapy, especially in patients with risk factors.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* IV pantoprazole is typically reserved for patients unable to take oral medications.
* Long-term PPI use is associated with increased risks, so use the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is for educational purposes and does not substitute for professional medical advice. Always verify current prescribing information and consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.
